Neonatal Abstinence Syndrome | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …

Prescription opioids are used prenatally for the management of pain, as well as for opiate
dependency. Opioids are known to cross the placenta and despite the evidence of possible …

Background Pregnancy is a unique opportunity to provide broad and necessary medical
care for women-including treatment for Substance Use Disorders (SUD). The standard of …

Background: There are few data regarding the utilization of opioids during pregnancy. The
objective of this study was to define the prevalence and patterns of opioid use in a large …

Objective To provide absolute and relative risk estimates of neonatal abstinence syndrome
(NAS) based on duration and timing of prescription opioid use during pregnancy in the …

Over the previous 2 decades, use of opioids grew dramatically across the United States. In
2015, 37% of American adults were prescribed at least one opioid pain reliever (OPR) 1—3 …

OUD affects 2.5 million Americans1 and is prevalent across all age groups and
backgrounds. It has contributed to increasing injection drug use as well as the spread of …

Increasing rates of maternal opioid use during pregnancy and neonatal withdrawal, termed
neonatal abstinence syndrome (NAS), are public health concerns. Prenatal buprenorphine …

Multiple studies have found that children born to mothers with opioid or poly-substance use
during pregnancy have more behavior and attention problems and lower cognitive …

OBJECTIVE: To compare neonatal abstinence syndrome prevalence and characteristics
among neonates born to women prescribed buprenorphine and naloxone compared with …